Startups
Edit
http://www.ionispharma.com/
Ionis Pharmaceuticals, Inc.
TrustedLast activity: 16.10.2026
Active
For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing the standard of care with its novel antisense technology. Ionis currently has three approved medicines and a premier late-stage pipeline highlighted by industry-leading neurological and cardiometabolic franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming one of the most successful biotechnology companies.
Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.
To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/.
Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/.
Spinraza is marketed by Biogen.
Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply.
Learn more about our history:
https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t
Attention Potential Applicants!
Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/
See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf
Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.
To learn more about Ionis follow us on twitter @ionispharma or visit https://www.ionispharma.com/.
Akcea Therapeutics is a wholly owned subsidiary of Ionis. Akcea commercializes TEGSEDI® and WAYLIVRA®. For more information about Akcea, visit: https://www.ionispharma.com/akcea/about-akcea/.
Spinraza is marketed by Biogen.
Ionis is proud to be recognized by the San Diego Business Journal as one of the 2020 Best Places to Work in San Diego. If you think you would be a good fit for our team, please visit the Jobs tab and apply.
Learn more about our history:
https://www.youtube.com/watch?v=xwwapOpQINM&list=PLihSIxoa7WLE1Makgl-bb82mSIO5fTKWF&index=2&t
Attention Potential Applicants!
Please be aware of employment scams using Ionis’ name and the names of Ionis employees to lure unsuspecting people into providing highly confidential and personal information. For more information visit: https://www.ionispharma.com/careers/how-to-identify-fake-job-advertisements/
See our community guidelines: https://www.ionispharma.com/wp-content/uploads/2019/05/Ionis-LinkedIn-Community-Guidelines-052019.pdf
Overview
Location
United States, New Mexico, Carlsbad
Employees
501-1000
Phone
+1 760-931-9200
Founded date
1989
Mentions in press and media 51
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 16, 2026 | Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG) | Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG) Fri, Oct 16, 2026 12:45 CET Report this content Positive CHMP opinion based on Phase 3 CORE and CORE2 results, demonstrat... |
| Oct 1, 2026 | NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) in adults in England and Wales | FOR UK HEALTHCARE/TRADE MEDIA ONLY Sobi® UK today announced that the National Institute for Health and Care Excellence (NICE) has issued final draft guidance which recommends Tryngolza® (olezarsen) as an option to treat genetically confirme... |
| Aug 9, 2026 | This teen once suffered hundreds of seizures a day. Now he can walk thanks to an experimental drug. | Getting your Trinity Audio player ready... Connor Dalby could not walk for the first 14 years of his life, so his newfound ability to scamper down hallways is miraculous on its own. But the experimental drug that reduced his severe and freq... |
| May 28, 2026 | Experimental hepatitis B drug may offer ‘functional cure’ for some patients | Getting your Trinity Audio player ready... By LAURAN NEERGAARD, AP Medical Writer WASHINGTON (AP) — A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what’s ... |
| May 26, 2026 | New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia | New analysis shows Tryngolza® (olezarsen) reduced acute pancreatitis by 85% and triglycerides by 66% in severe hypertriglyceridemia Tue, May 26, 2026 16:15 CET Report this content Sobi® (STO: SOBI) today announced results from a new analysi... |
| Mar 30, 2026 | EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG) | EMA validates indication extension application for Tryngolza® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG) Mon, Mar 30, 2026 08:00 CET Report this content Sobi® (STO: SOBI) today announced that the European Medicines ... |
| Feb 20, 2026 | Curt Smith: Fighting blood cancer is easier with a group effort | |
| Jan 30, 2026 | This 11-year-old has battled a rare disease for years — a breakthrough drug helped deliver relief | To share your story, or find out how to get involved with CNBC Cures, email [email protected] Susannah Rosen was diagnosed with a KIF1A gene mutation at the age of 2½. Patients diagnosed with severe KIF1A gene mutations may live only into... |
| Nov 8, 2025 | Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions | Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions Sat, Nov 08, 2025 15:40 CET Report this content Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has ... |
Show more
Reviews 0
FAQ about Ionis Pharmaceuticals, Inc.
When was Ionis Pharmaceuticals, Inc. founded?
Ionis Pharmaceuticals, Inc. was founded in 1989.
What has the press written about Ionis Pharmaceuticals, Inc.?
Parsers VC has collected 51 articles mentioning Ionis Pharmaceuticals, Inc., among them “Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)” (Oct 16, 2026) and “NICE issues final draft guidance recommending ▼ Tryngolza® (olezarsen) as an option to treat genetically confirmed familial chylomicronaemia syndrome (FCS) i...” (Oct 1, 2026).
Is Ionis Pharmaceuticals, Inc. still active?
Yes, Ionis Pharmaceuticals, Inc. is active; its latest activity on Parsers VC dates from Oct 16, 2026.